(Adds Ranbaxy CEO quotes)
TOKYO, Jan 15 (Reuters) - Ranbaxy Laboratories RANB.BO CEO Malvinder Mohan Singh said his firm was considering acquiring manufacturing facilities that already have approval from the U.S. Food and Drug Administration (FDA).
“We will transfer (production of) some products from India to America. Also, we are looking at making some acquisitions of manufacturing assets,” Singh told reporters at a media reception held by Japanese drugmaker Daiichi Sankyo (4568.T), which took a 63.9 percent stake in the Indian generic drugmaker last year.
He said his firm was looking for opportunities to buy FDA-approved facilities not only in the United States but also in other countries. (Reporting by Yumiko Nishitani; Editing by Hugh Lawson)